by MASA | Apr 15, 2026 | Asthma, Drug Updates, News, Severe Asthma, Type 2 Inflammation
In an interview on The Valder Beebe Show, Dr. Siri discusses the clinical and patient experience aspects of severe asthma. Over two millions Americans of various ages live with severe asthma out of 20-30 million people with asthma. From 0:30 to 3:55, Dr. Siri...
by MASA | Dec 19, 2024 | Drug Updates
The U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, for the treatment of mild, moderate, or severe atopic dermatitis (AD) in adults and children aged 2 years and older. This approval expands the use of VTAMA, previously approved for...
by MASA | Aug 15, 2024 | Drug Updates, Rare Diseases
What is D.R.E.S.S.? Drug Reaction with Eosinophilia and Systemic Symptoms (D.R.E.S.S.) is a type of drug allergy which can occur as a reaction to a large variety of medications. Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver...
by MASA | Jul 31, 2024 | Drug Updates
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
by MASA | Apr 23, 2024 | Drug Updates, News
The U.S. Food and Drug Administration (FDA) has provided an emergency use authorization (EUA) for a new medicine called Pemgarda™ (pemivibart), aimed at preventing COVID-19 in certain high-risk individuals. This medication is specifically designed for those who are...
by MASA | Mar 31, 2024 | Drug Updates
US FDA approved of XHANCE as the first and only medication for adults with chronic rhinosinusitis without nasal polyps. It is a fluticasone propionate nasal spray which uses the Exhalation Delivery System to enable topical steroid to the inflamed areas and is proven...
